The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Role of Chemotherapy in Gastric Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type

위말트림프종의 항암치료

  • Park, Yong (Division of Hematology/Oncology, Department of Internal Medicine, Korea University College of Medicine)
  • 박용 (고려대학교 의과대학 내과학교실)
  • Published : 2012.12.01
⟨ Previous Next ⟩

Abstract

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma comprises approximately 50% of primary gastric lymphoma. Currently, Helicobacter pyroli eradication is the mainstay in the management of localized gastric MALT lymphoma. However, other treatment strategies such as radiotherapy and chemotherapy should be required in certain circumstances which include H. pyroli-negative disease, H. pyroli-positive disease unresponsive to standard eradication, and advanced disease (stage III/IV). Here, we reviewed the role of chemotherapy in the management of patients with gastric MALT lymphoma based on recent clinical trials.

Keywords

References

  1. Neubauer A, Zucca E. Gastrointestinal tract lymphomas. In: Cavali F, Stein H, Zucca E, eds. Extranodal Lymphomas Pathology and Management. London: Informa Health Care, 2008:233-243.
  2. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104. https://doi.org/10.1016/S1470-2045(02)00651-4
  3. Zucca E, Bertoni F, Roggero E, Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000;96:410-419.
  4. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A, et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007;56:1685-1687. https://doi.org/10.1136/gut.2006.096420
  5. Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol 2009;20:1086-1093. https://doi.org/10.1093/annonc/mdn760
  6. Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005;23:8018-8024. https://doi.org/10.1200/JCO.2005.02.3903
  7. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397-400. https://doi.org/10.1093/oxfordjournals.annonc.a058869
  8. Nakamura S, Yao T, Aoyagi K, Iida M, Fujishima M, Tsuneyoshi M. Helicobacter pylori and primary gastric lymphoma: a histopathologic and immunohistochemical analysis of 237 patients. Cancer 1997;79:3-11. https://doi.org/10.1002/(SICI)1097-0142(19970101)79:1<3::AID-CNCR2>3.0.CO;2-P
  9. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176. https://doi.org/10.1016/0140-6736(91)92035-Z
  10. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report: gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747-758. https://doi.org/10.1136/gut.2010.224949
  11. National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines V.3.2012-Non-Hodgkin's lymphomas [Internet]. Fort Washington (PA): National Comprehensive Cancer Network, c2012. Available from: http://www.nccn.org/index.asp.
  12. Nakamura S, Matsumoto T, Ye H, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer 2006;107:2770-2778. https://doi.org/10.1002/cncr.22326
  13. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH, et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001;48:297-303. https://doi.org/10.1136/gut.48.3.297
  14. Steinbach G, Ford R, Glober G, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999;131:88-95. https://doi.org/10.7326/0003-4819-131-2-199907200-00003
  15. Raderer M, Streubel B, Wohrer S, Hafner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006;55:616-618. https://doi.org/10.1136/gut.2005.083022
  16. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-1983. https://doi.org/10.1200/JCO.2005.08.128
  17. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosaassociated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529. https://doi.org/10.1200/JCO.1995.13.10.2524
  18. Levy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061-5066. https://doi.org/10.1200/JCO.2005.05.660
  19. Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009;144:367-375. https://doi.org/10.1111/j.1365-2141.2008.07486.x
  20. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996;178:122-127. https://doi.org/10.1002/(SICI)1096-9896(199602)178:2<122::AID-PATH486>3.0.CO;2-D
  21. Hussell T, Isaacson PG, Spencer J. Proliferation and differentiation of tumour cells from B-cell lymphoma of mucosa-associated lymphoid tissue in vitro. J Pathol 1993;169:221-227. https://doi.org/10.1002/path.1711690208
  22. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20:3872-3877. https://doi.org/10.1200/JCO.2002.05.117
  23. Jager G, Neumeister P, Quehenberger F, Wohrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-1723. https://doi.org/10.1093/annonc/mdl126
  24. Wohrer S, Raderer M, Kaufmann H, et al. Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. Onkologie 2005;28:73-78. https://doi.org/10.1159/000083223
  25. Raderer M, Wohrer S, Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006;70:411-417. https://doi.org/10.1159/000098555
  26. Levy M, Copie-Bergman C, Molinier-Frenkel V, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma 2010;51:284-290. https://doi.org/10.3109/10428190903431820
  27. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer 2009;115:5210-5217. https://doi.org/10.1002/cncr.24605
  28. Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) Study. Ann Hematol 2012;91:543-551. https://doi.org/10.1007/s00277-011-1337-6
  29. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:6370-6378. https://doi.org/10.1200/JCO.2005.05.011
  30. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653. https://doi.org/10.1038/nrc1409
  31. Troch M, Jonak C, Mullauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009;94:738-742. https://doi.org/10.3324/haematol.2008.001537
  32. Stathis A, Bertoni F, Zucca E. Treatment of gastric marginal zone lymphoma of MALT type. Expert Opin Pharmacother 2010;11:2141-2152. https://doi.org/10.1517/14656566.2010.497141

Cited by

  1. Diagnosis and Treatment of Gastric Mucosa-associated Lymphoid Tissue Lymphoma vol.74, pp.6, 2019, https://doi.org/10.4166/kjg.2019.74.6.304